SMS Pharmaceuticals Q3 FY26: Revenue ₹210.45 Cr, PAT ₹23.47 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹210Cr
- +21.4% YoY
- −13.2% QoQ
- Net profit
- ₹23Cr
- +27.8% YoY
- −8% QoQ
- Margin
- 21%
- +2 pp YoY
- +1 pp QoQ
Guidance rank: #51 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on SMS Pharmaceuticals Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] - Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY [Page 6, 27] - Q3FY26 PAT after MI & Associate: ₹23.47 cror Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY - Q3FY26 EBITDA Margin: 21%, up 158 basis points YoY - Q3FY26 PAT: ₹23.47 crore, up 29% YoY - Q3FY26 PAT Margin: 11%, improved by 63 basis p
From SMS Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27]
- Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY [Page 6, 27]
- Q3FY26 PAT after MI & Associate: ₹23.47 crore, up 29% YoY [Page 27]
- EPS for Q3FY26: ₹2.59, up 20% YoY [Page 27, 6]
- Volume growth noted as a key driver for revenue increase; strong volume growth in key APIs highlighted [Page 5]
2 more points from SMS Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what SMS Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total capex spend planned: ₹280 crore, to be completed by FY27 (Page 25).
- Capex oriented towards:
- Capacity expansion for existing APIs.
- Building capacities for a new API pipeline.
- Land acquisition underway for a greenfield project (Page 25).
- Capex project mix: 89% brownfield (capacity expansion), 11% greenfield (new plant) (Page 25).
- Strategic focus post last 3-4 years' capex cycle is on asset utilization to deliver high-teen returns (Page 25).
2 more points from SMS Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what SMS Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what SMS Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
SMS Pharmaceuticals Ltd — Quarterly revenue & net profit
SMS Pharmaceuticals Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 210 | 173 | +21.4% | 242 | -13.2% |
| Operating profit (EBITDA) | 44 | 33 | +33.3% | 48 | -8.3% |
| Operating margin | 21% | 19% | +2 pp | 20% | +1 pp |
| Profit before tax | 31 | 22 | +40.9% | 34 | -8.8% |
| Net profit (PAT) | 23 | 18 | +27.8% | 25 | -8% |
| EPS (₹) | 2.51 | 2.15 | +16.7% | 2.70 | -7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹316 Cr, net profit ₹40 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What SMS Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
SMS Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were SMS Pharmaceuticals Ltd Q3 FY26 results?
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] - Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY [Page 6, 27] - Q3FY26 PAT after MI & Associate: ₹23.47 cror Q3FY26 EBITDA: ₹43.65 crore, up 31% YoY - Q3FY26 EBITDA Margin: 21%, up 158 basis points YoY - Q3FY26 PAT: ₹23.47 crore, up 29% YoY - Q3FY26 PAT Margin: 11%, improved by 63 basis p
What is SMS Pharmaceuticals Ltd share price analysis?
SMS Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 40.5 with a market cap of ₹4,148 Cr. Investors should review the full earnings analysis for detailed insights.
Is SMS Pharmaceuticals Ltd planning capital expenditure?
Total capex spend planned: ₹280 crore, to be completed by FY27 (Page 25).
Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
